David Gandara (@drgandara) ranks #17 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 13 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: MAVERICK (SWOG S1827), ADAURA, DESTINY-Lung04. CMS Open Payments lists $32,794 in 2025 general payments.
At a Glance
- 5 posts naming a trial in 2026
- 5 trials discussed by name
- Lung Cancer: US #17, Global #40 · 13 physicians engaged
- Presented at ESMO 2026, WCLC 2026 in 2026
- CMS Open Payments lists $32,794 in 2025 general payments.
This Month
What David Gandara has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies David Gandara
Physicians who reposted David Gandara’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #17 | #40 | 13 | 19 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions David Gandara presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ESMO 2026 · Proffered paper (3809O)ASTRIDE: Randomized Trial of Serplulimab or Atezolizumab Plus Chemotherapy in USA Patients With Extensive-Stage Small Cell Lung CancerASTRIDE trial profile → · Source: @HHorinouchi on X ↗
- WCLC 2026 · Mini oral (MO05.07)EMPOWER-Lung 1: KRAS G12C Predicts Superior Outcomes With 1L Cemiplimab for Non-Squamous NSCLC With PD-L1 >=50%Source: @HHorinouchi on X ↗
What Colleagues Are Saying About David Gandara
2026 posts by fellow physicians that mention @drgandara, quoted word for word.
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥ASTRIDE: Randomized Trial of Serplulimab or Atezolizumab Plus Chemotherapy in USA Patients With Extensive-Stage Small Cell Lung Cancer 🎙️ @drgandara 🔢3809O 🎯Serplulimab Numerically Longer OS vs Atezolizumab 🎯mOS 12.4 vs 10.2m, HR 0.82; 24-Mo OS 32.2% vs 17.6% ☑️NCT05468489 🔗 https://t.co/grEfaUchKN @OncoAlert @Larvol @myESMO @IASLC
@DoctorJSpicer Impressive for 8 weeks of therapy! Will be interesting to see how next gen G12C mono vs combination with PD1 plays out. @drgandara will be presenting #wclc26 data on cemiplimab mono therapy in advanced Kras g12c that looks remarkably similar to G12Ci/PD1 combo data. https://t.co/vYZMMF6mAy
Congrats to @drgandara on presenting ASTRIDE at #ESMO26! Randomized bridging trial in US pts with ES-SCLC: serplulimab vs atezolizumab + chemo -mOS 12.4 vs 10.2 mo (HR 0.82) -24-mo OS 32.2% vs 17.6% -Similar safety Supports ASTRUM-005 findings in US pts @myESMO @isliquidbiopsy https://t.co/QqD3ZuWlsD
Excellent presentation by @drgandara on KRASG12C analysis im non-squamous NSCLC INNTHE EMPOWER Lung-01. Interesting data in a largest cohort in the topic. Congrats!! @KRASKickers @IASLC #WCLC26 https://t.co/SqWOybVpqj
Trials David Gandara Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| MAVERICK (SWOG S1827) | 1 | #7 of 33 | Sep 13, 2026 |
| ADAURA | 1 | #9 of 41 | Sep 13, 2026 |
| DESTINY-Lung04 | 1 | #29 of 37 | Aug 17, 2026 |
| MARIPOSA | 1 | #14 of 14 | Jul 22, 2026 |
| CROWN | 1 | #24 of 36 | May 29, 2026 |
David Gandara on MAVERICK (SWOG S1827)
MAVERICK trial. This KM curve says it all. It's RIP for PCI in SCLC. @SWOG https://t.co/njpBBUv1aH
David Gandara on ADAURA
wCLC2026 At Presidential Plenary @DrRoyHerbst gives 8 year update on ADAURA, adjuvant osimertinib in surgically resected EGFR mutated early stage NSCLC. Bravo! 👏 https://t.co/v3Tnn8unZC
David Gandara on DESTINY-Lung04
Re- Destiny-Lung04, Phase III of T-DXd vs Chemo in HER2-mutated NSCLC . Big news, although these results anticipated. Will it translate into improved overall survival? https://t.co/28MVd2vhae
David Gandara on MARIPOSA
Re MARIPOSA trial, thanks @StephenVLiu for important update. Helps define long-term risk versus benefit for this regimen. I am convinced that there is rationale for looking toward the "light at the end of the tunnel". Was data on ctDNA included? @IASLC @isliquidbiopsy https://t.co/Av2Wh07H3E [QUOTED] Report on time to symptomatic progression from phase III MARIPOSA study in EGFR mutant NSCLC available. Median was 43.6m with 1L amivantamab + lazertinib compared to 29.3m with osimertinib (HR 0.69). TTSP strongly correlated with PFS and OS. https://t.co/bBYvXSNIOd
David Gandara on CROWN
#ASCO26 Extraordinary long term data from the Lorlatinib CROWN trial presented by Tony Mok. Median PFS still not reached at 7 years. Are some of these patients actually cured with a TKI or does this remain disease suppression? https://t.co/AEeg1omDAt
David Gandara’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Congratulations to Tina Cascone & colleagues on strong work in plasma ctDNA determination of MRD. Clearly prognostic. Clearance association with pCR informative. Ongoing trials such as INSIGHT will help determine benefit of postoperative immunotherapy component in those with pCR https://t.co/6C6oVEHHAb
Boom! 💥 That is the sound of another previously untargetable KRAS subset struck down by novel "ON" inhibitors, presented by my friend and colleague J Riess. ~73% of ctDNA-evaluable patients (N=15) had complete clearance from plasma. So happy to see. @riess_md @isliquidbiopsy https://t.co/iAMhpHbbaZ
#ASCO26. DZD6008, on track to fill a huge unmet need: C797S+ EGFR-mutated NSCLC after OSI. Impressive data. https://t.co/IGBOT6ZfRW
#ASCO26. Metastatic NSCLC session. Dan Tan summarizes the "Precision Oncology Paradox" after the first 3 abstract presentations. Some clarity. More to learn. https://t.co/CKiwjGTTNa
Hi @PTarantinoMD -The "Truck Test" for highly positive OS KM curve of Daraxonrasib in mPDAC. 👏👏👏 https://t.co/wyxFqrqgre
Industry Payments
CMS Open Payments · 2025 general payments
$32,794 across 36 payments